AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer

AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer

Source: 
Fierce Pharma
snippet: 

AstraZeneca and Merck are racing against GlaxoSmithKline to snag an expanded nod for Lynparza in ovarian cancer patients who responded to their first round of chemo. And with a priority nod from the FDA, the partners just got a boost that could put them ahead.